DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Femring (Estradiol Acetate Vaginal) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

 The following serious adverse reactions are discussed elsewhere in the labeling:

  • Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions (5.1)].
  • Malignant Neoplasms [see Boxed Warning, Warnings and Precautions (5.2)].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

 In a 13-week clinical trial that included 225 postmenopausal women treated with Femring and 108 women treated with placebo vaginal rings, adverse reactions that occurred at a rate of ≥ 2 percent are summarized in Table 1.

Table 1. Incidence of Adverse Reactions Occurring in ≥ 2 Percent of Subjects Presented in Descending Frequency of Preferred Term

Adverse Event Placebo
(n=108)
 
Estradiol
 0.05 mg/day     
(n=113)

Estradiol 
  0.10mg/day      
(n=112)

  n (percent) n (percent) n (percent)

 Headache (NOS)

10 (9.3) 8 (7.1) 11 (9.8)
 Intermenstrual Bleeding 2 (1.9) 9 (8.0) 11 (9.8)
 Vaginal Candidiasis 3 (2.8) 7 (6.2) 12 (10.7)
 Breast Tenderness 2 (1.9) 7 (6.2) 12 (10.7)
 Back Pain 4 (3.7) 7 (6.2) 4 (3.6)
 Abdominal Distension 3 (2.8) 8 (7.1) 3 (2.7)
 Sinusitis (NOS) 2 (1.9) 2 (1.8) 4 (3.6)
 Uterine Pain 1 (0.9) 2 (1.8) 5 (4.5)
 Urinary Tract Infection (NOS) 2 (1.9) 1 (0.9) 4 (3.6)
    AE = adverse event; NOS = not otherwise specified  

Postmarketing Experience

1.    A few cases of toxic shock syndrome (TSS) have been reported in women using vaginal rings. TSS is a rare, but serious disease that may cause death. Warning signs of TSS include fever, nausea, vomiting, diarrhea, muscle pain, dizziness, faintness, or a sunburn-rash on face and body.

2.       A few cases of ring adherence to the vaginal or bladder wall, making ring removal difficult, have been reported in women using vaginal rings. Patients should be carefully evaluated for vaginal or bladder wall ulceration or erosion. If an ulceration or erosion has occurred, consideration should be given to leaving the ring out and not replacing it until healing is complete to prevent the ring from adhering to the vaginal tissue.

3.       A few cases of bowel obstruction associated with vaginal ring use have been reported. Persistent abdominal complaints consistent with obstruction should be carefully evaluated.

4.       A few cases of inadvertent ring insertion into the urinary bladder, which may require surgical removal, have been reported for women using vaginal rings. Persistent unexplained urinary symptoms should be carefully evaluated.

The following additional adverse reactions have been identified during post-approval use of Femring. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary system
Uterine cancer, vaginal hemorrhage, ovarian cyst, irregular menstruation, metrorrhagia, menorrhagia, dysmenorrhea, uterine enlargement.

Breasts
Breast cancer, fibrocystic breast disease, breast disorder, breast mass, breast enlargement, breast pain, nipple pain, breast discharge.

Cardiovascular
Chest pain, increased blood pressure, irregular heart rate, pulmonary embolism, cerebrovascular accident (stroke), hemiparesis, transient ischemic attack, thrombosis.

Gastrointestinal
Abdominal pain, pancreatitis, cholecystitis, cholelithiasis, vomiting.

Skin
Generalized erythema, erythema multiforme, erythema nodosum, rash, hirsutism, pruritis.

Eyes
Blindness, contact lens intolerance.

Central Nervous System
Dizziness, headache, depression, nervousness, mood disturbances, irritability.

Miscellaneous
Medical device complication, back pain, angioedema, weight increased/decreased, edema, libido increased/decreased, urticaria, hypersensitivity, anaphylaxis.



REPORTS OF SUSPECTED FEMRING SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Femring. The information is not vetted and should not be considered as verified clinical evidence.

Possible Femring side effects / adverse reactions in 50 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-03

Patient: 50 year old female weighing 50.8 kg (111.8 pounds)

Reactions: Drug Effect Decreased

Suspect drug(s):
Femring



See index of all Femring side effect reports >>

Drug label data at the top of this Page last updated: 2014-05-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017